AN OPEN-LABEL, PARALLEL GROUP, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERATION OF MARAVIROC ADMINISTERED TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRED AND NORMAL RENAL FUNCTION
Latest Information Update: 04 May 2013
At a glance
- Drugs Maraviroc (Primary) ; Ritonavir; Saquinavir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 19 Dec 2012 New trial record